Stock ScreenerStock IdeasZen Ratings + Top AnalystsStocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: Sep 7, 2025The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.
Stock ScreenerStock IdeasZen Ratings + Top Analysts
Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | $688.27B | $727.21 | $914.75 | 25.79% | 32.84% | Strong Buy | Strong Buy | 8 | 5 | 17.10% | 35.91% | 240.26% | 43.50% |
| RYAAY | RYANAIR HOLDINGS PLC | $32.19B | $60.51 | $76.00 | 25.60% | 25.60% | Strong Buy | Strong Buy | 1 | 1 | 9.01% | 17.13% | 70.10% | 28.18% |
| WIX | WIXCOM LTD | $8.56B | $153.10 | $214.84 | 40.33% | 39.61% | Strong Buy | Strong Buy | 19 | 16 | 10.47% | 19.02% | -474.66% | 27.98% |
| BGC | BGC GROUP INC | $4.71B | $9.94 | $14.50 | 45.88% | 40.85% | Strong Buy | Strong Buy | 2 | 1 | 13.38% | 280.65% | 70.09% | 13.33% |
| IHS | IHS HOLDING LTD | $2.44B | $7.27 | $9.38 | 28.95% | 23.80% | Strong Buy | Strong Buy | 6 | 2 | 1.21% | 15.47% | -66.91% | 4.04% |
| DBD | DIEBOLD NIXDORF INC | $2.19B | $59.90 | $75.00 | 25.21% | 25.21% | Strong Buy | Strong Buy | 2 | 2 | 4.10% | N/A | 20.10% | 5.90% |
| FIVN | FIVE9 INC | $2.06B | $26.70 | $33.86 | 26.81% | 34.21% | Buy | Strong Buy | 14 | 6 | 7.11% | 119.23% | 22.62% | 9.52% |
| ARDT | ARDENT HEALTH PARTNERS INC | $1.88B | $13.16 | $18.23 | 38.52% | 51.98% | Buy | Strong Buy | 7 | 4 | 4.46% | 5.31% | 29.09% | 7.26% |
| NTCT | NETSCOUT SYSTEMS INC | $1.77B | $24.86 | $33.00 | 32.74% | 32.74% | Strong Buy | Strong Buy | 1 | 1 | 3.75% | N/A | N/A | N/A |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $1.74B | $8.27 | $17.13 | 107.07% | 137.00% | Strong Buy | Strong Buy | 8 | 5 | 10.64% | N/A | -51.62% | 47.60% |
| AVDL | AVADEL PHARMACEUTICALS PLC | $1.53B | $15.76 | $22.75 | 44.35% | 58.63% | Buy | Strong Buy | 4 | 3 | 24.41% | N/A | 165.98% | 80.45% |
| GBX | GREENBRIER COMPANIES INC | $1.46B | $47.16 | $57.00 | 20.87% | 20.87% | Strong Buy | Strong Buy | 1 | 1 | N/A | -24.28% | 11.40% | 3.94% |
| DCO | DUCOMMUN INC | $1.35B | $90.45 | $119.75 | 32.39% | 32.39% | Strong Buy | Strong Buy | 4 | 4 | 4.67% | 57.59% | 9.66% | 5.93% |
| LMB | LIMBACH HOLDINGS INC | $1.25B | $107.85 | $159.50 | 47.89% | 47.89% | Strong Buy | Strong Buy | 2 | 2 | 19.26% | 42.74% | 32.49% | 16.15% |
| EVER | EVERQUOTE INC | $859.51M | $23.54 | $34.00 | 44.44% | 44.44% | Strong Buy | Strong Buy | 2 | 2 | 8.48% | 11.69% | 40.39% | 28.48% |
| NRDS | NERDWALLET INC | $795.79M | $10.68 | $14.25 | 33.43% | 33.43% | Strong Buy | Strong Buy | 4 | 4 | 6.18% | 26.83% | 12.03% | 9.41% |
| AKBA | AKEBIA THERAPEUTICS INC | $777.40M | $2.96 | $6.90 | 133.11% | 142.13% | Strong Buy | Strong Buy | 5 | 3 | 20.35% | N/A | 422.04% | 33.44% |
| TBPH | THERAVANCE BIOPHARMA INC | $702.54M | $13.95 | $24.50 | 75.63% | 79.21% | Strong Buy | Strong Buy | 2 | 1 | 16.01% | N/A | -2.24% | -1.18% |
| KMDA | KAMADA LTD | $410.59M | $7.14 | $13.00 | 82.07% | 82.07% | Strong Buy | Strong Buy | 2 | 2 | 7.80% | 18.34% | 13.94% | 9.84% |
| ELMD | ELECTROMED INC | $204.30M | $24.47 | $35.50 | 45.08% | 43.03% | Strong Buy | Strong Buy | 2 | 1 | N/A | N/A | N/A | N/A |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have access to Premium? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.